PubRank

P Hillmen

Author PubWeight™ 37.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 6.29
2 International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007 2.96
3 Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001 1.99
4 Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994 1.80
5 ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012 1.68
6 Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000 1.40
7 Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy. Br J Haematol 1996 1.38
8 Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 1994 1.34
9 Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 1.24
10 Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2012 1.14
11 Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007 1.12
12 Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21. Hum Mol Genet 1994 1.00
13 Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med 1994 0.93
14 The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999 0.90
15 Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. Blood 1995 0.90
16 Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998 0.89
17 Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006 0.87
18 Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1994 0.83
19 Primary thrombocythaemia in pregnancy. Br J Haematol 1991 0.83
20 Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. Haematologica 1997 0.82
21 Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria. Blood 1992 0.80
22 Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults. Leukemia 2006 0.80
23 Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J 2013 0.80
24 Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. Haematologica 2007 0.79
25 Both paroxysmal nocturnal hemoglobinuria (PNH) type II cells and PNH type III cells can arise from different point mutations involving the same codon of the PIG-A gene. Blood 1997 0.79
26 Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. Blood 1998 0.78
27 Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood 2000 0.78
28 Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure. Leuk Res 2010 0.77
29 Paroxysmal nocturnal haemoglobinuria: nature's gene therapy? Mol Pathol 2002 0.77
30 Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. Blood 1994 0.77
31 The evolving role of alemtuzumab in management of patients with CLL. Leukemia 2005 0.75
32 Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that thymic T-cell production declines with age. Blood 1999 0.75